Mycoplasma penetrans bacteremia and primary antiphospholipid syndrome. by Yáñez, A. et al.
164 Emerging Infectious Diseases Vol. 5, No. 1, JanuaryFebruary 1999
Dispatches
Antiphospholipid syndrome (APS), first
described in 1983 to 1986, is characterized by a
wide variety of hemocytopenic and vaso-
occlusive manifestations and is associated with
antibodies directed against negatively charged
phospholipids. Features of APS include hemolyt-
ic anemia, thrombocytopenia, venous and
arterial occlusions, livedo reticularis, pulmonary
manifestations, recurrent fetal loss, neurologic
manifestations (stroke, transverse myelitis,
Guillain-Barré syndrome); and a positive
Coombs test, anticardiolipin antibodies, or lupus
anticoagulant activity (1). The factor(s) causing
production of the antiphospholipid antibodies in
primary antiphospholipid syndrome (PAPS)
remain unidentified (2).
A substantial number of patients with
Mycoplasma pneumoniaeinduced respiratory
disease have anticardiolipin antibodies (3).
Furthermore, many clinical criteria for APS
have also been well documented in patients
with  M. pneumoniae infection, including
Guillain-Barrélike illness and other central
nervous system manifestations, hemolytic ane-
mia, positive Coombs test, thrombocytopenia,
and arthritis (4).
In this report, we describe the case of a
patient with clinical features of PAPS and a
documented bacteremic infection due to
M. penetrans (5).
Case
One month before hospital admission, a
previously healthy non-HIV-infected 17-year-old
woman (blood group O Rh+) who had not
previously received a blood transfusion and had
not had sexual experience had acute onset of
arthritis of both ankles, generalized arthralgias,
fever, progressive asthenia, and hemolytic
anemia (hemoglobin 87 g/L, unconjugated
bilirubin 25.1 µmol/L). In the 30 days before
hospital admission she had not received
medications other than nonsteroidal antiinflam-
matory drugs for 5 days. Three days before
hospital admission, she became ill with
respiratory distress, generalized weakness,
anorexia, and inability to walk.
On admission to the hospital (day 1), physical
examination showed severe pallor, a swollen
cervical lymph node, slight edema of both legs,
tachycardia, and no hypertension. Laboratory
data showed severe hemolytic anemia (hemoglo-
bin 34 g/L, lactate dehydrogenase 5.1  µmol/s/L),
leukocytosis (24.5 x 109/L), thrombocytopenia
(28.0 x 109/L), and normal renal function. A
Coombs test was positive at 4ºC, 22ºC, and 37ºC.
Blood and bone marrow smears did not show a
neoplasic process. The nonsteroidal antiinflam-
matory drugs were suspended, and treatment
was started with a combination of methylpred-
nisolone (1 gm bolus q24h intravenously [i.v.] for
3 days) and trimethoprim/sulfamethoxazole (80/
400 mg q12h orally) on day 2, but her condition
deteriorated. On day 3, the antibiotic treatment
was changed to ceftazidime (1 gm q8h i.v.).
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Transfusion was not attempted because serologic
tests indicated the lack of compatibility; (there
was a strong positive mismatch incompatibility
in 55 different blood samples and a mild
mismatch in one sample). Another transfusion
was partially rejected because of unidentified
nonspecific antibodies. On day 4 severe
respiratory distress and hypoxemia developed,
requiring a ventilator, and the patient was
admitted to the intensive care unit. Livedo
reticularis was noted, and methylprednisolone
(125 mg q8h i.v.) was administered. Venereal
Disease Research Laboratory tests were nega-
tive as were tests for lupus erythematosus. The
patient had anti-dsDNA antibodies (Kallestad
Quantafluor Crithidia lucilae Sanofi Diagnostic
Pasteur, Inc.) but positive anticardiolipin
antibodies by enzyme-linked immunosorbent
assay (ELISA) (100 GPL units) (negative test = <10
GPL units) (ImmunoWell, Cardiolipin Antibody
Immunoglobulin [Ig]G ELISA; and Reaads
Medical Products, Inc.), which remained positive
4 and 12 months later, and antiplatelet
antibodies by immunofluorescence (Anti-Human
IgG H-chain Fluorescein conjugated, OTIY-05
Behring Diagnostics). Laboratory data showed
hemoglobin 33 g/L, leukocyte 23.6 x 109/L, a
prolonged activated partial thromboplastin time
>150 seconds (control <42 seconds) and
prothrombin time of 26.1 seconds (control 14.0
seconds), International Normalized Ratios value
= 3D 2.09, and the presence of lupus
anticoagulant (LA) antibodies (prolonged Russell
viper venom time and confirmed by the
STACLOT LA ELISA test, Reaads Medical
Products, Inc.). Respiratory secretions were
culture-negative and negative by immunofluo-
rescence for respiratory syncytial virus, adenovi-
rus, influenza A, influenza B, parainfluenza
1,2,3, and Chlamydia. Serologic analysis
indicated that the patient had no antibodies
against HIV, hepatitis B surface and core
antigens (HbsAg, HBc), or hepatitis C virus. No
acid-fast bacilli or other bacteria were observed
on blood and tracheal aspirate smears. In
addition, thoracic radiography showed only
bilateral diffuse pulmonary infiltrates, which
was not suggestive of an anaerobic infection.
On day 2 of hospital admission, blood and
throat samples were cultured for aerobic flora
and mycoplasma. M. penetrans in pure culture
was isolated from the patients blood (isolate HF-
1) and throat (isolate HF-3). Later M. penetrans
was isolated from tracheal aspirate in pure
culture (isolate HF-2). Treatment was initiated
on day 6 with clindamycin 600 mg q8h i.v. and
vancomycin 500 mg q6h i.v. The patient also
received transfusion of two units of washed red
blood cells.
By the microbroth dilution method (6), the
HF-1 isolate was sensitive to clindamycin,
clarithromycin, azithromycin, erythromycin, tet-
racycline, doxycycline, ofloxacin, and chloram-
phenicol but resistant to vancomycin and
gentamicin. After 3 days of treatment, the
patient improved clinically and was released from
the intensive care unit on day 9; thoracic
radiographs were clear.
The unique evidence of thrombosis was a
low-degree paresthesia of both legs while the
patient was receiving anticoagulant therapy;
when the condition developed, anticoagulant
therapy was increased. The patient received
physiotherapy to correct paresis and reduced
sensation in the left foot and ankle region. She
left the hospital after 26 days, with minimal
evidence of peripheral neuropathy as a sequela.
M. penetrans infection was detected in the
patients specimens prior to culture and was
confirmed by specific polymerase chain reaction
(PCR) (7) (Figure 1A, 1B). Similar results were
obtained by another pair of PCR primers also
within the 16S rRNA gene and designed for the
specific detection of M. penetrans (data not
Figure 1. Polymerase chain reaction (PCR) detection
of  Mycoplasma penetrans in clinical samples. A.
M. penetrans PCR genomic amplification with the
primers MYCPENET-P and MYCPENET-N (7) and
analyzed by electrophoresis in 2% agarose gel.
Lysates from the following original samples: throat
swab (lane 1); tracheal aspirate (lane 2); blood (lane
3);  first blood subculture (HF-1 isolate) (lane 4);
M. penetrans GTU-54-6A1 (lane 5), showing the
amplification product of 407-bp; and negative control
(lane 6). B. Southern blotting of the same material.
Hybridization with the internal oligonucleotide
(MYCPENET-S) probe confirmed the specific
amplification of M. penetrans genetic sequences.166 Emerging Infectious Diseases Vol. 5, No. 1, JanuaryFebruary 1999
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minor differences were found, in particular for
antigens approximately 38 kDa in both SDS and
Triton X-114 extracts. Ultrastructural examina-
tion of the HF isolates by transmission electron
microscopy showed mycoplasma cells with
morphologic features typical of M. penetrans
(Figure 2B).
Serologic assays (ELISA and Western blot)
with Triton X-114-extracted antigens and other
M. penetrans polypeptides from whole-cell
lysates both from the type strain GTU-54-6A1
and from our isolate HF-1 were done as
previously described (10). A lack of reactivity
against the Triton X-114extracted antigens of
M. penetrans was observed by both methods.
However, with whole-cell extracts from both type
strain and the HF-1 isolate, a 20-kDa
polypeptide  was immunodetected by Western
blotting with three serum samples collected on
days 2, 4, and 9 of hospitalization. The 20-kDa
polypeptide is an M. penetrans product, but
whether the observed reaction corresponds to a
cross-reacting epitope is not known. The
patients samples were also negative for
antibodies against M. pneumoniae, M. genitalium,
and M. fermentans by ELISA (11) (data not
shown).
Conclusions
Since  M. penetrans was first reported in 1993
as an emerging infectious agent, M. penetrans
specific antibodies have been detected more
frequently (18.2% to 35.4%) in HIV-infected than
in non-HIV-infected persons (0.4% to 1.3%) (10).
Until this case, M. penetrans had only been
isolated eight times (5,10), always from the urine
of HIV-infected persons (10).
The results indicating that the isolates HF-1,
HF-2, and HF-3 belong to the M. penetrans
species are as follows: 1) clinical samples and the
mycoplasmal isolates obtained from them were
positive in the M. penetrans-specific PCR assay;
2) protein patterns of the HF isolates and the
type strain of M. penetrans GTU-54-6A1 were
almost identical; 3) serum samples from different
patients (10), which contained M. penetrans-
specific antibodies on the basis of a reaction with
the p35 antigen from the type strain of
M. penetrans also reacted with a similar Triton
X-114extracted polypeptide from the HF-1
isolate; and 4) HF isolates exhibited typical
morphologic features of M. penetrans, which are
unique among mycoplasmas isolated from
Figure 2. HF isolates belong to the species Mycoplasma
penetrans. A. Comparison of protein patterns from the
type strain of M. penetrans and the isolate HF-1.
Mycoplasma cells were directly lysed with SDS (cell
lysate), or antigens were extracted with the neutral
detergent Triton X-114 (total extract). Antigens were
further separated after partitioning between the
aqueous and detergent phases. The two mycoplasmas
compared are the M. penetrans type strain GTU-54-6A1
(GTU) and the isolate HF. B. Ultrastructural features of
the M. penetrans isolates HF-1, HF-2 and HF-3. The HF
isolates were passaged four times in SP-4 broth without
antibiotics and processed for transmission electron
microscopy (TEM). Ultrathin sections were stained
with osmiun tetroxide and ruthenium red and observed
by TEM. The three isolates show the typical elongated,
flask-shaped morphology of M. penetrans, with the two
divided internal compartments. The cytoplasm is
limited by a single triple-layered unit membrane that is
covered with capsular material.
shown). Samples from both original specimens
and broth cultures were tested by PCR for other
human mycoplasmas (8,9), but none were
detected (data not shown).
The sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) protein pat-
terns of different extracts (whole cell lysate,
Triton X-114 extracts) for the isolate HF-1 and
the type strain GTU-54-6A1 were almost
identical (Figure 2A). Upon close examination,167 Vol. 5, No. 1, JanuaryFebruary 1999 Emerging Infectious Diseases
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humans. The fact that serum from other patients
reacted with a similar polypeptide from HF
isolates indicates that this protein is produced by
this strain of M. penetrans. The lack of M.
penetrans strong humoral response in the HF
patient was a factor in favor of dissemination of
the mycoplasma, hence its isolation from the
blood. A possible association between M.
penetrans and PAPS should be considered.
Snowden et al. (1990) found antiphospholipid
antibodies in more than 50% of patients with
M. pneumoniae pneumonia, especially those
with severe infections requiring hospitalization
(3). Catteau et al. (1995) described two cases of
Stevens-Johnson syndrome associated with
M. pneumoniae infection and the presence of
antiphospholipid antibodies (12). Our patient
had manifestations typical of PAPS (2). Thus,
this report is the first of M. penetrans isolation in
a non-HIV-infected patient and the first of a
blood and respiratory tract infection with
M. penetrans.
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